Diabetes
Commented by Carsten Mainitz on November 10th, 2026 | 05:45 CET
Exciting pharma duel: Who will take off now - BioNxt Solutions, Bayer or Novo Nordisk?
New active ingredients, expanded indications and more user-friendly dosage forms are driving momentum in the global pharmaceutical market. BioNxt Solutions is focusing on novel oral dissolvable films and working towards regulatory and clinical breakthroughs. Industry heavyweights Bayer and Novo Nordisk have recently reported solid quarterly results. Bayer has already overcome several challenges and raised its outlook. At the same time, Novo Nordisk is impressively demonstrating how innovative forms of administration in obesity treatment can achieve soaring commercial success. Where do the most attractive opportunities for investors lie following the latest developments?
Read
Commented by Armin Schulz on November 4th, 2026 | 05:33 CET
Stocks for Healthier Harvests – Novo Nordisk, MustGrow Biologics and Nestlé at the Intersection of Appetite and Agriculture
Created and published on behalf of MustGrow Biologics Corp.
Living a healthier life today also means managing one's appetite medically. People who lose weight change their eating habits and pay closer attention to where their food comes from. This brings agricultural land into focus, as it is there that the foundations are laid for producing healthy crops for consumers. At the end of October, a provider of biological crop protection products reported successful field trials in Europe. At the end of the value chain is the food group that turns harvested crops into products for health-conscious consumers. We therefore take a closer look at Novo Nordisk, MustGrow Biologics and Nestlé.
Read
Commented by Armin Schulz on October 27th, 2026 | 05:21 CET
Pharma Stocks with a Future: Bayer, BioNxt Solutions and Novo Nordisk Expand Their Pipelines
No pharmaceutical company can rely on its bestsellers forever. Eventually, patent protection expires, generic manufacturers enter the market, and margins come under pressure. Companies that fail to replenish their product pipelines risk being left behind. That is why substantial sums are currently flowing into new active ingredients, manufacturing facilities and innovative drug delivery methods. Bayer plans to invest USD 2.2 billion in a pharmaceutical plant in Ohio. Smaller developers such as BioNxt Solutions are exploring new formulations and delivery methods for established active ingredients. At the end of September, Novo Nordisk agreed to license an oral drug candidate, including an upfront payment of USD 300 million. We take a closer look at Bayer, BioNxt Solutions and Novo Nordisk.
Read